213,285 Orion Corporation A shares converted into B shares
September 20 2024 - 1:30AM
UK Regulatory
213,285 Orion Corporation A shares converted into B shares
ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO
THE RULES OF THE EXCHANGE
20 SEPTEMBER 2024 at 9.30 EEST
213,285 Orion Corporation A shares converted into B
shares
In accordance with Section 3 of the Articles of Association of
Orion Corporation, 213,285 A shares have been converted into
213,285 B shares. The conversion has been entered into the Trade
Register on 20 September 2024.
The total number of shares in Orion Corporation is 141,134,278
which, after the conversion, consists of 32,974,309 A shares and
108,159,969 B shares. The number of votes of the company's shares
is after the conversion 767,646,149.
Orion Corporation
René Lindell
CFO |
|
Olli Huotari
SVP, Corporate Functions |
|
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426
2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being for over a hundred years. We develop,
manufacture and market human and veterinary pharmaceuticals and
active pharmaceutical ingredients. Orion has an extensive portfolio
of proprietary and generic medicines and consumer health products.
The core therapy areas of our pharmaceutical R&D are oncology
and pain. Proprietary products developed by Orion are used to treat
cancer, neurological diseases and respiratory diseases, among
others. Orion's net sales in 2023 amounted to EUR 1,190 million and
the company had about 3,600 employees at the end of the year.
Orion's A and B shares are listed on Nasdaq Helsinki.
Orion (TG:OFK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Orion (TG:OFK)
Historical Stock Chart
From Dec 2023 to Dec 2024
